Roche
NEWS
Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, have launched a collaboration to discover and develop new therapies for fibrotic diseases.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
The FDA’s Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD.
According to news reports, a six-year-old girl in North Texas was provided Tamiflu and had a rare reaction that affected her nervous system.
Here’s a look at the seven best life science companies to work for in 2018.
Patients who received Tecentriq and Avastin in addition to standard chemo showed a 38 percent reduction in the risk of the disease getting worse or death.
Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents.
Genentech scored two approvals from the FDA this week.
The drug will be used to prevent or reduce the frequency of bleeding episodes in certain patients.
JOBS
IN THE PRESS